Next Article in Journal
Clinical and Laboratory Characteristics of Normal Weight and Obese Individuals with Non-Alcoholic Fatty Liver Disease
Next Article in Special Issue
Mir-29b in Breast Cancer: A Promising Target for Therapeutic Approaches
Previous Article in Journal
Current Value of Biparametric Prostate MRI with Machine-Learning or Deep-Learning in the Detection, Grading, and Characterization of Prostate Cancer: A Systematic Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 12
Issue 4
10.3390/diagnostics12040800
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis

by
Manuel Scimeca
1,2,3,*,
Manuela Montanaro
1,
Rita Bonfiglio
1,
Lucia Anemona
1,
Enrico Finazzi Agrò
4,
Anastasios D. Asimakopoulos
4,
Roberto Bei
5,
Vittorio Manzari
5,
Nicoletta Urbano
6,
Erica Giacobbi
1,
Francesca Servadei
1,
Elena Bonanno
1,
Orazio Schillaci
7,8 and
Alessandro Mauriello
1
1
Department of Experimental Medicine, University of Rome “Tor Vergata”, Via Montpellier 1, 00133 Rome, Italy
2
San Raffaele University, Via di Val Cannuta 247, 00166 Rome, Italy
3
Faculty of Medicine, Saint Camillus International University of Health Sciences, Via di Sant’Alessandro 8, 00131 Rome, Italy
4
Department of Surgical Sciences, Division of Urology, University of Rome Tor Vergata, 00133 Rome, Italy
5
Department of Clinical Sciences and Translational Medicine, University of Rome “Tor Vergata”, 00133 Rome, Italy
6
Nuclear Medicine Unit, Department of Oncohaematology, Policlinico “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy
7
Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Via Montpellier 1, 00133 Rome, Italy
8
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, Via Atinense, 18, 86077 Pozzilli, Italy
*
Author to whom correspondence should be addressed.
Diagnostics 2022, 12(4), 800; https://doi.org/10.3390/diagnostics12040800
Submission received: 25 February 2022 / Revised: 22 March 2022 / Accepted: 23 March 2022 / Published: 24 March 2022
(This article belongs to the Special Issue Predictive and Prognostic Biomarkers of Human Cancer in Italy)
Browse Figures
Review Reports Versions Notes

Abstract

The main aim of this study was to investigate the risk of prostate cancer metastasis formation associated with the expression of ETS homologous factor (EHF) in a cohort of bioptic samples. To this end, the expression of EHF was evaluated in a cohort of 152 prostate biopsies including primary prostate cancers that developed metastatic lesions, primary prostate cancers that did not develop metastasis, and benign lesions. Data here reported EHF as a candidate immunohistochemical prognostic biomarker for prostate cancer metastasis formation regardless of the Gleason scoring system. Indeed, our data clearly show that primary lesions with EHF positive cells ≥40% had a great risk of developing metastasis within five years from the first diagnosis. Patients with these lesions had about a 40-fold increased risk of developing metastasis as compared with patients with prostate lesions characterized by a percentage of EHF positive cells ≤30%. In conclusion, the immunohistochemical evaluation of EHF could significantly improve the management of prostate cancer patients by optimizing the diagnostic and therapeutic health procedures and, more important, ameliorating the patient’s quality of life.
Keywords: prostate cancer; ETS homologous factor; metastasis; histological marker prostate cancer; ETS homologous factor; metastasis; histological marker

Share and Cite

MDPI and ACS Style

Scimeca, M.; Montanaro, M.; Bonfiglio, R.; Anemona, L.; Agrò, E.F.; Asimakopoulos, A.D.; Bei, R.; Manzari, V.; Urbano, N.; Giacobbi, E.; et al. The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis. Diagnostics 2022, 12, 800. https://doi.org/10.3390/diagnostics12040800

AMA Style

Scimeca M, Montanaro M, Bonfiglio R, Anemona L, Agrò EF, Asimakopoulos AD, Bei R, Manzari V, Urbano N, Giacobbi E, et al. The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis. Diagnostics. 2022; 12(4):800. https://doi.org/10.3390/diagnostics12040800

Chicago/Turabian Style

Scimeca, Manuel, Manuela Montanaro, Rita Bonfiglio, Lucia Anemona, Enrico Finazzi Agrò, Anastasios D. Asimakopoulos, Roberto Bei, Vittorio Manzari, Nicoletta Urbano, Erica Giacobbi, and et al. 2022. "The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis" Diagnostics 12, no. 4: 800. https://doi.org/10.3390/diagnostics12040800

APA Style

Scimeca, M., Montanaro, M., Bonfiglio, R., Anemona, L., Agrò, E. F., Asimakopoulos, A. D., Bei, R., Manzari, V., Urbano, N., Giacobbi, E., Servadei, F., Bonanno, E., Schillaci, O., & Mauriello, A. (2022). The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis. Diagnostics, 12(4), 800. https://doi.org/10.3390/diagnostics12040800

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop